Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynthomer Regulatory News (SYNT)

Share Price Information for Synthomer (SYNT)

Share Price is delayed by 15 minutes
Get Live Data
104.00    0.80 (0.78%)
Bid:
100.20
Ask:
105.80
Spread: 5.60 (5.589%)
Market Cap: £170.50m
SYNT Live PriceLast checked at - London Stock Exchange

Intraday Synthomer Share Chart

Disposal

5 Jan 2009 11:17

RNS Number : 0853L
Yule Catto & Co PLC
05 January 2009
Β 

ο»Ώ5 January 2009

Yule Catto & Co plc

Disposal of Oxford Chemicals Limited

Yule Catto & Co plcΒ ("the Group"),Β an international producer ofΒ specialtyΒ chemicalsΒ usedΒ in a wide range of industries includingΒ pharmaceuticals, FMCG, paints and adhesives,Β is pleased to announce thatΒ it has exchanged conditional contracts withΒ Frutarom (UK) LimitedΒ forΒ the saleΒ of the business and assets of Oxford Chemicals LimitedΒ for a consideration ofΒ Β£8.25Β million.Β Β The considerationΒ will be paidΒ in full in cash at completion.

The completion of the sale is conditional onΒ regulatory approval for the transfer of operational licences and compliance with employee information and consultation requirements.

The proceeds of the sale will be used to reduce theΒ Group's borrowings.

Oxford ChemicalsΒ develops, manufacturesΒ and suppliesΒ high impact aromaΒ chemicals andΒ other specialty aroma chemicals.Β Β In the twelveΒ months to 31 December 2007Β it had sales of Β£9.7Β million, an operating profit ofΒ Β£0.6Β million and gross assets of Β£6.4Β million.

TheΒ Oxford ChemicalsΒ management team led byΒ Anthony WestonΒ will continue to runΒ the business.

Adrian Whitfield, Chief Executive,Β commented:

"We are now in the final stages of implementing our statedΒ strategyΒ of divestingΒ the Impact Chemicals division,Β withΒ gross proceedsΒ to dateΒ reaching some Β£63 million."

Recent update

Yule Catto issued an update on 29 December 2008, the full text of which isΒ repeated below.

Yule Catto & Co plc ("the Group") is pleased to announce that it has signed aΒ newΒ three year Β£30 million revolving loan facility with its principal banks, HSBC and Barclays. This loan replaces its existing revolving bank loan facility maturing in November 2009.

During the course of this re-financing, the Board has been carefully considering the capital structure of the Group. Whilst much progress has been made on the deleveraging of the balance sheet, with Β£55 million of gross proceeds received from the sale of three of our five Impact Chemicals businesses*, the balance sheet remains a core focus of the Board and it aims to reduce outstanding net debt to below Β£100 millionΒ over the next twelve to twenty four months. The Board believes this is consistent with the Group's objectives, including itsΒ financial commitments to the Group'sΒ UKΒ pension fund.

Accordingly, and in light of the current financial environment and economic uncertainty, the Board has additionally decided to suspend the payment of dividends until such time as net debt is nearer to its overall target and at which time the business environment and financial market conditions may well have improved. The Board anticipates reverting to the payment of a dividend within two years.

At the time the Group recommences the payment of a dividend, the Board anticipates rebasing it to a level determined by comparison with its peer group and which will allow an appropriate free cash flow to suit the Group's circumstances.

The Board is also pleased to confirm that for 2008 the Group still expects to deliver underlying earnings before tax modestly ahead of last year, despite the current difficult economic conditions particularly in theΒ UKΒ and Continental Europe. The Board believes it is too early at this time, given the prevailing economic uncertainty, to offer any firm guidance on the outturn for 2009. The Group's ImpactΒ ChemicalsΒ and PharmaΒ ChemicalsΒ businesses should benefit next year from recent restructuring. Within our PolymerΒ ChemicalsΒ business we anticipate the performance of our Asian andΒ Middle EastΒ businesses to be more robust than that of our European businesses, due to local market conditions and a more resilient demand profile from our targeted markets. In addition, the current relative weakness ofΒ SterlingΒ against the Dollar, Euro and Malaysian Ringgit, should it continue, will assist the reportedΒ SterlingΒ earnings for a number of our businesses.

The Group continues to look at ways to improve efficiency and minimise costs. We currently have a number of initiatives in hand to do this, both withinΒ EuropeΒ and the rest of the world.Β 

These are exceptional times, with a high degree of market uncertainty and a very difficult environment for funding. Having completed Β£55 million of divestments*Β and put in place a new revolving loan, the Board believes that, together with internal actions to conserve cash and the suspension of the dividend, Yule Catto is now well placed to weather these conditions.

(* before the disposal ofΒ OxfordΒ Chemicals announced today)

- Ends -

For further information, please contact:

Β 

Yule Catto & Co plcΒ 
Adrian Whitfield, Chief ExecutiveΒ 
David Blackwood, Group Finance Director
Β 
01279 442791
Hogarth Partnership
John Olsen
Andrew Jaques
Ian Payne
020 7357 9477
07770 272082

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
DISILFLLLSIEIIA
Date   Source Headline
11th Nov 20212:24 pmRNSDirector/PDMR Shareholding
4th Nov 20212:11 pmRNSDirector/PDMR Shareholding
1st Nov 20217:00 amRNSNew Chief Executive
28th Oct 20213:17 pmRNSResult of Placing
28th Oct 20217:00 amRNSAcquisition
28th Oct 20217:00 amRNSPROPOSED PLACING OF NEW ORDINARY SHARES
30th Sep 20213:08 pmRNSDirectorate Change
10th Sep 20218:23 amRNSDirector Declaration
5th Aug 20217:01 amRNSBoard Update
5th Aug 20217:00 amRNSInterim Results
20th Jul 202112:05 pmRNSSynthomer plc receives Green Economy Mark
19th Jul 20217:00 amRNSTrading Update
14th Jul 202111:02 amRNSDirector/PDMR Shareholding
9th Jul 20217:00 amRNSAppointment of Non-Executive Director
6th Jul 202112:37 pmRNSDirector/PDMR Shareholding
25th Jun 202110:01 amRNSFurther re Appointment of Group CEO
23rd Jun 20217:00 amRNSAppointment of Group Chief Executive Officer
18th May 20213:53 pmRNSDirector Declaration
12th May 20212:56 pmRNSDirector Declaration
6th May 20214:17 pmRNSDirector Declaration
6th May 20213:15 pmRNSDirector/PDMR Shareholding
29th Apr 20214:01 pmRNSResult of AGM
21st Apr 20217:00 amRNSQ1 Trading Update
31st Mar 20219:00 amRNSDirector/PDMR Shareholding
31st Mar 20219:00 amRNSDirector/PDMR Shareholding
30th Mar 202110:56 amRNSAnnual Financial Report
19th Mar 20212:38 pmRNSDirector/PDMR Shareholding
12th Mar 20213:17 pmRNSDirector/PDMR Shareholding
12th Mar 20213:16 pmRNSDirector/PDMR Shareholding
12th Mar 20213:14 pmRNSDirector/PDMR Shareholding
12th Mar 20213:14 pmRNSDirector/PDMR Shareholding
11th Mar 20219:43 amRNSHolding(s) in Company
4th Mar 202112:43 pmRNSPreliminary results – correction
4th Mar 20217:00 amRNSPreliminary Results year ended 31 December 2020
1st Mar 202112:58 pmRNSHolding(s) in Company
24th Feb 20217:00 amRNSStatement RE: Press Speculation
22nd Feb 20214:40 pmRNSSecond Price Monitoring Extn
22nd Feb 20214:35 pmRNSPrice Monitoring Extension
19th Feb 20213:38 pmRNSHolding(s) in Company
14th Jan 20217:00 amRNSPre-Close Trading Update and Board Update
12th Jan 20219:36 amRNSHolding(s) in Company
6th Jan 20219:10 amRNSDirector Declaration
4th Jan 202110:09 amRNSDirector Declaration
23rd Dec 20204:54 pmRNSDirector/PDMR Shareholding
17th Dec 20207:00 amRNSAppointment of New Chair
18th Nov 20207:00 amRNSInvestor Seminar
17th Nov 20201:34 pmRNSDirector/PDMR Shareholding
16th Oct 202010:33 amRNSHolding(s) in Company
14th Oct 20207:00 amRNSQ3 Trading Update
7th Oct 20209:20 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.